SILA trades 0.1% above Wall Street's consensus target of $30.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SILA achieves its forward estimates and maintains a stable P/E multiple of 46.7x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Sila Realty Trust, Inc. (SILA) has a Wall Street consensus price target of $30.33, based on estimates from 4 covering analysts. With the stock currently trading at $30.36, this represents a potential downside of -0.1%. The company has a market capitalization of $1.68B.
Analyst price targets range from a low of $30.00 to a high of $31.00, representing a 3% spread in expectations. The median target of $30.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SILA trades at a trailing P/E of 50.6x and forward P/E of 46.7x. Analysts expect EPS to grow -4.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $32.10, with bear and bull scenarios of $20.22 and $42.29 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CHCTCommunity Healthcare Trust Incorporated | $516M | $18.05 | $18.50 | +2.5% | Hold | 38.4x | 16 |
GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
MDRRMedalist Diversified REIT, Inc. | $14M | $11.23 | — | — | — | — | — |
HRHealthcare Realty Trust Incorporated | $7.1B | $20.40 | $21.83 | +7.0% | Hold | — | 30 |
OHIOmega Healthcare Investors, Inc. | $14.6B | $49.02 | $50.43 | +2.9% | Hold | 24.7x | 28 |
SBRASabra Health Care REIT, Inc. | $5.0B | $19.73 | $21.00 | +6.4% | Hold | 29.2x | 29 |
LTCLTC Properties, Inc. | $2.0B | $38.77 | $36.00 | -7.1% | Hold | 20.6x | 22 |
CTRECareTrust REIT, Inc. | $9.8B | $41.39 | $44.25 | +6.9% | Buy | 27.7x | 19 |
NHINational Health Investors, Inc. | $3.7B | $76.00 | $82.83 | +9.0% | Hold | 21.6x | 19 |
WELLWelltower Inc. | $163.0B | $232.69 | $237.80 | +2.2% | Buy | 80.3x | 35 |
Quick answers to the most common questions about buying SILA stock.
Wall Street's consensus price target for SILA is $30.33, -0.1% from its current price of $30.36. The below-market target from 4 analysts suggests limited near-term appreciation.
SILA has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $30.33 implies -0.1% downside from current levels.
At a forward P/E of 46.7077x, SILA trades at a premium valuation. The consensus price target of $30.33 (-0.1% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $31 for SILA, while the most conservative target is $30. The consensus of $30.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $42 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SILA is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SILA stock forecast based on 4 Wall Street analysts shows a consensus price target of $30.33, with estimates ranging from $30 (bear case) to $31 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $32, with bear/bull scenarios of $20/$42.
Our quantitative valuation model calculates SILA's fair value at $32 (base case), with a bear case of $20 and bull case of $42. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
SILA trades at a forward P/E ratio of 46.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 50.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on SILA, with 0 Sell ratings and a price target of $30.33 (-0.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SILA analyst price targets range from $30 to $31, a 3% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30.33 consensus represents the middle ground. Our model's $20-$42 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.